|
Inogen, Inc. (INGN) DCF -Bewertung
US | Healthcare | Medical - Devices | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Inogen, Inc. (INGN) Bundle
Our Inogen, Inc. (INGN) DCF-Taschenrechner, der für die Genauigkeit entwickelt wurde, ermöglicht es Ihnen, die Bewertung von Inogen mit realen Finanzdaten zu bewerten, und bietet vollständige Flexibilität, um alle wichtigen Parameter für erweiterte Projektionen zu ändern.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 308.5 | 358.0 | 377.2 | 315.7 | 335.7 | 345.3 | 355.2 | 365.4 | 375.8 | 386.6 |
| Revenue Growth, % | 0 | 16.05 | 5.37 | -16.32 | 6.35 | 2.86 | 2.86 | 2.86 | 2.86 | 2.86 |
| EBITDA | 6.6 | 30.9 | -25.0 | -58.3 | -42.5 | -18.7 | -19.2 | -19.7 | -20.3 | -20.9 |
| EBITDA, % | 2.13 | 8.62 | -6.61 | -18.48 | -12.66 | -5.4 | -5.4 | -5.4 | -5.4 | -5.4 |
| Depreciation | 18.6 | 21.6 | 23.5 | 18.2 | .0 | 16.6 | 17.1 | 17.6 | 18.1 | 18.6 |
| Depreciation, % | 6.02 | 6.04 | 6.23 | 5.75 | 0 | 4.81 | 4.81 | 4.81 | 4.81 | 4.81 |
| EBIT | -12.0 | 9.2 | -48.5 | -76.5 | -42.5 | -35.3 | -36.3 | -37.3 | -38.4 | -39.5 |
| EBIT, % | -3.9 | 2.58 | -12.85 | -24.23 | -12.66 | -10.21 | -10.21 | -10.21 | -10.21 | -10.21 |
| Total Cash | 231.2 | 245.5 | 187.0 | 128.5 | 113.8 | 184.9 | 190.2 | 195.6 | 201.2 | 207.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 31.8 | 25.8 | 64.4 | 42.9 | 29.6 | 39.3 | 40.5 | 41.6 | 42.8 | 44.0 |
| Account Receivables, % | 10.3 | 7.21 | 17.06 | 13.59 | 8.81 | 11.39 | 11.39 | 11.39 | 11.39 | 11.39 |
| Inventories | 24.8 | 31.9 | 34.1 | 21.8 | 24.8 | 27.8 | 28.6 | 29.4 | 30.3 | 31.2 |
| Inventories, % | 8.04 | 8.9 | 9.04 | 6.92 | 7.39 | 8.06 | 8.06 | 8.06 | 8.06 | 8.06 |
| Accounts Payable | 12.5 | 10.3 | 18.2 | 13.5 | .0 | 11.1 | 11.4 | 11.7 | 12.0 | 12.4 |
| Accounts Payable, % | 4.06 | 2.87 | 4.83 | 4.26 | 0 | 3.2 | 3.2 | 3.2 | 3.2 | 3.2 |
| Capital Expenditure | -17.6 | -24.1 | -21.2 | -27.0 | .0 | -18.4 | -18.9 | -19.4 | -20.0 | -20.6 |
| Capital Expenditure, % | -5.7 | -6.72 | -5.63 | -8.56 | 0 | -5.32 | -5.32 | -5.32 | -5.32 | -5.32 |
| Tax Rate, % | 1.61 | 1.61 | 1.61 | 1.61 | 1.61 | 1.61 | 1.61 | 1.61 | 1.61 | 1.61 |
| EBITAT | -13.3 | -6.8 | -48.8 | -76.6 | -41.8 | -28.1 | -28.9 | -29.7 | -30.6 | -31.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -56.4 | -12.5 | -79.3 | -56.5 | -44.9 | -31.6 | -32.3 | -33.3 | -34.2 | -35.2 |
| WACC, % | 8.44 | 8.08 | 8.44 | 8.44 | 8.43 | 8.37 | 8.37 | 8.37 | 8.37 | 8.37 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -131.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -36 | |||||||||
| Terminal Value | -564 | |||||||||
| Present Terminal Value | -377 | |||||||||
| Enterprise Value | -508 | |||||||||
| Net Debt | -94 | |||||||||
| Equity Value | -414 | |||||||||
| Diluted Shares Outstanding, MM | 24 | |||||||||
| Equity Value Per Share | -17.51 |
What You Will Get
- Real INGN Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Inogen's future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Customizable Financial Inputs: Adjust key metrics such as revenue growth, EBITDA %, and capital expenditures for accurate forecasting.
- Instant DCF Valuation: Quickly calculates intrinsic value, NPV, and other essential financial outputs.
- High-Precision Accuracy: Incorporates Inogen, Inc.'s (INGN) actual financial data for credible valuation results.
- Effortless Scenario Testing: Easily explore various assumptions and analyze different outcomes.
- Efficiency Booster: Streamlines the valuation process, eliminating the need for complex model building from the ground up.
How It Works
- Download: Obtain the pre-configured Excel file containing Inogen, Inc.'s (INGN) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various forecasts and compare results instantly.
- Make Decisions: Leverage the valuation findings to inform your investment strategy.
Why Choose This Calculator for Inogen, Inc. (INGN)?
- Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and financial consultants.
- Comprehensive Data: Inogen's historical and projected financials are preloaded for precise analysis.
- Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and other essential metrics.
- User-Friendly: Clear, step-by-step instructions facilitate the entire process.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling Inogen, Inc. (INGN) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for Inogen, Inc. (INGN).
- Consultants: Deliver professional valuation insights on Inogen, Inc. (INGN) to clients quickly and accurately.
- Business Owners: Understand how companies like Inogen, Inc. (INGN) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to Inogen, Inc. (INGN).
What the Template Contains
- Pre-Filled DCF Model: Inogen, Inc.’s financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Inogen, Inc.’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.